KalVista Pharmaceuticals, Inc. announced that William C. Fairey has been appointed to the company?s Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc. and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases. Mr. Fairey has more than 30 years of experience in commercial and medical operations in the biotechnology and pharmaceutical industry, including shaping markets, developing products, determining global commercial/medical strategies, and leading cross-functional teams in delivering successful new product launches.

Prior to MyoKardia, he served as Chief Operating Officer at ChemoCentryx, Inc. and held several positions of increasing responsibility at Actelion Pharmaceuticals, including serving as President for its US division, Vice President of the Asia Pacific Region, and President of Actelion Canada. He has also held several senior business, sales and market access roles at the Parke-Davis division of Warner-Lambert and has previously served on several life science company boards. Mr. Fairey received his M.B.A. from St.

Mary?s College of California and his B.S. from the University of Oregon.